Product Pathways - Screening Technologies
PTMScan® Phospho-PKA Substrate Motif (RRXS*/T*) Kit #5565
|5565S||1 Kit (5 assays)||In Stockfirstname.lastname@example.org|
|Products Included||Quantity||Cap Color|
|PTMScan® Phospho-PKA Substrate Motif (K/RK/RXS*/T*) Immunoaffinity Beads||10 x 80 µl||Blue|
|PTMScan® IAP Buffer (10X)||10 x 0.6 ml||White|
|PTMScan® Limited Use License|
Directions For Use
Cells are lysed in a urea-containing buffer, cellular proteins are digested by proteases, and the resulting peptides are purified by reversed-phase, solid-phase extraction. Peptides are then subjected to immunoaffinity purification using a PTMScan® antibody conjugated to protein A agarose beads. Unbound peptides are removed through washing, and the captured PTM-containing peptides are eluted with dilute acid. Reversed-phase purification is performed on microtips to desalt and separate peptides from antibody prior to concentrating the enriched peptides for LC-MS/MS analysis. CST recommends the use of PTMScan® IAP Buffer #9993 included in the kit. An alternate PTMScan® IAP Buffer Plus Detergent #9992 which may reduce nonspecific interactions is available separately. A detailed protocol and Limited Use License allowing the use of the patented PTMScan® method is included with the kit.
PTMScan® Technology employs a proprietary methodology from Cell Signaling Technology for peptide enrichment by immunoprecipitation using a specific bead-conjugated antibody in conjunction with liquid chromatography (LC) tandem mass spectrometry (MS/MS) for quantitative profiling of post-translational modification (PTM) sites in cellular proteins. These include phosphorylation (PhosphoScan®), ubiquitination (UbiScan®), acetylation (AcetylScan®), and methylation (MethylScan®), among others. PTMScan® enables researchers to isolate, identify and quantitate large numbers of post-translationally modified cellular peptides with a high degree of specificity and sensitivity providing a global overview of PTMs in cell and tissue samples without preconceived biases about where these modified sites occur (1). For more information on PTMScan® services, please visit www.cellsignal.com/services/index.html.
Chart showing the proportions of underlying sequence motifs found in a PTMScan study using PKA substrate antibody and Orbitrap LC-MS analysis. Combined analysis of two experiments (#10619, #10620) on peptides from PC-12 cells gave 187 non-redundant sites containing PKA substrate and related motifs. The primary motifs are highlighted in white. The proportion containing phosphoserine was 82%, and the proportion with arginine residues at both the -3 and -2 positions (PKA substrate motif) was 64%. Although this antibody has a strong preference for the PKA substrate motif, it also recognizes peptides with just an arginine residue at the -3 position.
An important class of kinases, refered to as Arg-directed kinases or AGC-family kinases, includes cAMP-dependent protein kinase (PKA), cGMP-dependent protein kinase (PKG), protein kinase C, Akt, and RSK. These kinases share a substrate specificity characterized by Arg at position -3 relative to the phosphorylated Ser or Thr (2,3). Phospho-PKA substrate-specific antibodies from CST are powerful tools for investigating the regulation of phosphorylation by PKA and other Arg-directed kinases, as well as for high throughput kinase drug discovery.
In this assay, PTMScan® (RRXS*/T*) Motif Antibody bead conjugates are used to specifically enrich phospho- peptides containing the RRXS*/T* motif (S* = phospho- serine, T*= phospho-threonine).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
PTMScan® is a trademark of Cell Signaling Technology, Inc.
UbiScan® is a trademark of Cell Signaling Technology, Inc.
AcetylScan® is a trademark of Cell Signaling Technology, Inc.
MethylScan® is a trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
Select rabbit monoclonal antibodies are developed, validated, and produced at CST using in part technology under license (granting certain rights including those under U.S. Patents No. 5,675,063 and in some instances 7,429,487) from Epitomics, Inc.
Use of Cell Signaling Technology (CST) Motif Antibodies within certain methods (e.g., U.S. Patents No. 7,198,896 and 7,300,753) may require a license from CST. For information regarding academic licensing terms please have your technology transfer office contact CST Legal Department at CST_ip@cellsignal.com. For information regarding commercial licensing terms please contact CST Pharma Services Department at email@example.com.